| Identification | Back Directory | [Name]
CYP11B2-IN-1 | [CAS]
1356479-78-1 | [Synonyms]
CYP11B2-IN-1
CYP11B2 IN 1,CYP-11B2-IN-1,CYP11B2IN1
2-[5-(1-cyclopropyl-6-fluoro-1h-benzimidazol-2-yl)pyridin-3-yl]propan-2-ol
3-Pyridinemethanol, 5-(1-cyclopropyl-6-fluoro-1H-benzimidazol-2-yl)-α,α-dimethyl- | [Molecular Formula]
C18H18FN3O | [MDL Number]
MFCD32671341 | [MOL File]
1356479-78-1.mol | [Molecular Weight]
311.35 |
| Chemical Properties | Back Directory | [Boiling point ]
528.5±60.0 °C(Predicted) | [density ]
1.34±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
13.62±0.29(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
CYP11B2-IN-1 is a CYP11B2 inhibitor with an IC50 of 2.3 nM. CYP11B2-IN-1 inhibits CYP11B1 with an IC50 of 142 nM[1]. | [in vivo]
In a rhesus pharmacodynamic model, CYP11B2-IN-1 (Compound 32) produces dose-dependent aldosterone lowering efficacy, with no apparent effect on cortisol levels[1].
CYP11B2-IN-1also displays a good rhesus pharmacokinetics profile, with low plasma clearance and acceptable oral exposure.When dosed i.v. at 0.01 and 0.3 mg/kg, CYP11B2-IN-1 produces reductions in aldosterone AUC of 62% and 95%, respectively, compared to baseline[1]. | [IC 50]
CYP11B2: 2.3 nM (IC50); CYP11B1: 142 nM (IC50) | [References]
[1] Hoyt SB, et al. Discovery of Benzimidazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys.ACS Med Chem Lett. 2015 Apr 7;6(5):573-8. DOI:10.1021/acsmedchemlett.5b00054 |
|
|